In part 5 of this Exclusive Interview, Dr. Ray Kausik talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 convention in San Diego, CA about PCSK9 inhibitors cost in the U.S. versus Europe.
Ray Kausik, MB, ChB, MD, is Professor of Public Health in the Department of Public Health and Primary Care at Imperial College London as well as Honorary Consultant Cardiologist at the Imperial College NHS Trust.
Transcript of this video segment:
Freed: I know they’re very expensive… [PCSK9 inhibitors]
Kausik: They are in the United States. The cost in the U.S. is about 14 and a half thousand dollars. In Europe, it’s actually a lot cheaper, it’s probably about $5,000 to 5 and half thousand dollars, so, it’s actually a lot, lot cheaper in Europe.
Freed: It actually pays to go to Europe. (Laughs)
Kausik: And get your 1-year subscription, yeah. (Laughing)
Freed: So the National Health Services, especially in the UK, they pay for that.
Kausik: Yes, so the NHS in the UK has agreed to pay for it, but there is a certain threshold. I’m going to have to do the conversion in my head….probably with people who have been on statin therapy, who have established vascular disease and familial hypercholesterolemia with an LDL of around about 130-140 still, they would get reimbursed. And they’ve got a slight discounted rate with the companies. The group for primary prevention for familial hypercholesterolemia is despite statin therapy with an LDL above around about 190, so they then get it. Your LDL has to be very high despite treatment, or your risk has to be very high with a slightly lower LDL, which is slightly different from where the trials were done because they were an even lower risk population. But that’s at the level that the UK NHS has decided it’s cost-effective.
To view other segments in this video series:
Part 2: PCSK9 Effect On HDL Goal Levels